IP Library Granted Patent US 12691135
Granted Patent B2
US 12691135 · App. 18/045,906 · Granted Jul 28, 2026

Inhibitors of micro-RNA 22

Inventors: Pier Paolo Pandolfi (Boston, MA); Riccardo Panella (Boston, MA); Sakari Kauppinen (Aalborg, DK); Andreas Petri (Aalborg, DK)
Assignees: Beth Israel Deaconess Medical Center; Aalborg University; Resalis Therapeutics srl
A61K31/7125A61K31/712A61P3/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691135
App. No.
18/045,906
Granted
Jul 28, 2026
Kind
B2
Abstract

The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.

Claims (6)

1 . A miR-22 inhibitory composition comprising a nucleic acid having a sequence selected from the group consisting of: G*T*t*c*T*TC*a*A*c*T*G*g*C*a*g*C*T (SEQ ID NO: 17), G*T*t*C*t*T*c*A*a*CT*g*g*c*A*g*C*T (SEQ ID NO: 19), and G*T*t*c*T*T*c*A*a*C*t*g*G*CA*g*C*T (SEQ ID NO: 20), wherein the capital letters are LNA modifications, the lower case are unmodified, the symbol * denotes PS linkages, and the absence of the * symbol denotes PO linkages.

2 . A pharmaceutical composition comprising the nucleic acid of claim 1 , and a pharmaceutically acceptable excipient or carrier.

3 . A vector or plasmid comprising a sequence encoding the nucleic acid molecule according to claim 1 .

4 . A host cell comprising the nucleic acid of claim 1 .

5 . A method for inhibiting miR-22 comprising contacting miR-22 with a miR-22 inhibitory composition of claim 1 .

6 . A method of treating obesity in a subject, the method comprising administrating the pharmaceutical composition according to claim 2 to the subject.